Le Lézard
Classified in: Health
Subject: PDT

TransMed Announces New Oncology Clinical Research Technologies


CUPERTINO, Calif., Feb. 15, 2018 /PRNewswire-PRWeb/ -- TransMed Systems announces the availability of our new TransMed Trialstm family of oncology clinical research technologies. By using real-world evidence to make data-driven insights, TransMed Trials is designed to advance the state of the practice for clinical researchers including Pharma, CROs, and Research Networks for Site Selection, and Academic Centers and Oncology Providers for Patient Screening.

"Our new TransMed Trials technology solutions represent the culmination of a significant research and development effort and customer engagement experience, and I'm very proud of our entire team's effort to bring to market such a sophisticated technology focused on solving the problem of finding patients for complex clinical trials," says Nick Berens, CEO of TransMed. "These technology solutions represent a new approach to the pervasive industry challenge of accelerating patient enrollment. The TransMed Trials family of solutions combines our Precision Medicine Data Platform incorporating patented data science, applications, NLP, machine learning and expert clinical engagement professionals, to address head-on the difficult challenges facing clinical research teams in predictably identifying productive sites and enrolling more patients."

The new family of TransMed Trials solutions are designed to assist clinical researchers as follows:

TransMed Trials is for the first time truly unlocking patient data regardless of which electronic medical records (EMR) system an oncology provider uses. TransMed Trials identifies patients for clinical trials based on EMR data, a deep understanding of patients' pathology and histology reports, laboratory results, molecular diagnostic results and other disparate data sources. The TransMed Trials technology and clinical support is deployed across a large number of oncology practices, Academic Medical Centers, and integrated Health Systems enabling treating physicians and research staff to match patients who meet the eligibility criteria for their open oncology studies. The technology solution helps practices open revenue-generating trials that match their unique patient populations.

To learn more about the TransMed Trials family of clinical trial technologies, visit http://www.xbtransmed.com

About TransMed Systems, Inc.

TransMed Systems provides Precision Medicine software and Clinical Research solutions that facilitate the exploration, reporting and analysis of clinical, molecular and healthcare operational data. TransMed's unlocks the potential of the healthcare repository by tightly integrating analytics with aggregated data, thus providing sophisticated matching of potential clinical trial patients to complex clinical trials to accelerate patient enrollment. Our solutions are used by clinical research teams in Life Science companies, CROs, oncology service lines in community, health system and academic settings.

 

SOURCE TransMed Systems, Inc.


These press releases may also interest you

at 18:23
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...



News published on and distributed by: